2-(4-Methyl-piperazin-1-yl)-benzothiazole-5-carboxylic acid | 1638696-04-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(4-Methyl-piperazin-1-yl)-benzothiazole-5-carboxylic acid
• 英文别名: 2-(4-Methyl-1-piperazinyl)-5-benzothiazolecarboxylic acid；2-(4-methylpiperazin-1-yl)-1,3-benzothiazole-5-carboxylic acid
• CAS: 1638696-04-4
• 化学式: C₁₃H₁₅N₃O₂S
• 分子量: 277.347
• InChiKey: GYJXFMLLKFOOQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-(4-Methylpiperazin-1-yl)benzo[d]thiazole-5-carbonitrile 在 盐酸 作用下， 反应 3.0h， 以100%的产率得到2-(4-Methyl-piperazin-1-yl)-benzothiazole-5-carboxylic acid
  参考文献：
  名称：

  [EN] COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS
  [FR] COMPOSÉS POUR LE TRAITEMENT DE LA TUBERCULOSE RÉSISTANTE AUX MÉDICAMENTS ET PERSISTANTE

  摘要：

  本文描述了用于治疗耐药和持续结核病的化合物和组合物。本文还描述了一种筛选生物膜形成抑制剂的方法。

  公开号：

  WO2014190199A1

文献信息

• [EN] NADPH OXIDASE 4 INHIBITORS<br/>[FR] INHIBITEURS DE LA NADPH OXYDASE 4
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2016207785A1

  公开（公告）日：2016-12-29

  The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.

  该发明涉及Formula (I)的2,5-二取代苯并噁唑和苯并噻唑衍生物，其中L、X、Y和环(A)如描述中所述，它们的制备以及它们作为药用活性化合物的用途。这些化合物可能对预防或治疗与受损的活性氧自由基（ROS）产生相关的疾病或紊乱，以及预防或治疗各种纤维化疾病具有用处。
• NADPH oxidase 4 inhibitors
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US10584118B2

  公开（公告）日：2020-03-10

  The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.

  本发明涉及式 (I) 的 2,5-二取代苯并恶唑和苯并噻唑衍生物 其中 L、X、Y 和环（A）如描述中所述，它们的制备及其作为药用活性化合物的用途。所述化合物可用于预防或治疗与活性氧（ROS）生成受损有关的疾病或紊乱，和/或预防或治疗各种纤维化疾病。
• NADPH OXIDASE 4 INHIBITORS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP3310767A1

  公开（公告）日：2018-04-25
• 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP3310767B1

  公开（公告）日：2020-07-22
• COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS
  申请人：THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH

  公开号：US20160194299A1

  公开（公告）日：2016-07-07

  Described herein are compounds and compositions for treating drug resistant and persistent tuberculosis. Also described herein is a method of screening for identifying biofilm formation inhibitors.